background
littl
known
antivir
respons
sinonas
mucos
tissu
patient
chronic
rhinosinus
cr
object
investig
presenc
viru
express
tolllik
receptor
tlr
interferon
interferonstimul
gene
isg
healthi
mucos
tissu
control
subject
inflammatori
sinu
mucos
tissu
cr
patient
evalu
whether
level
interferon
isg
might
affect
crsrelat
cytokin
treatment
macrolid
dexamethason
agonist
method
presenc
viru
sinonas
mucosa
evalu
realtim
pcr
express
interferon
isg
sinonas
mucosa
cultur
epitheli
cell
treat
h
h
cytokin
macrolid
dexamethason
agonist
evalu
realtim
pcr
western
blot
express
sinonas
mucosa
evalu
immunohistochemistri
result
respiratori
virus
detect
sampl
interferon
isg
express
normal
mucosa
level
decreas
patient
cr
interferon
isg
level
upregul
cell
treat
macrolid
dexamethason
agonist
decreas
cytokinetr
cell
level
show
signific
differ
normal
inflammatori
sinu
mucos
tissu
conclus
result
suggest
decreas
level
interferon
isg
patient
cr
might
contribut
impair
antivir
innat
respons
inflammatori
sinonas
epitheli
cell
macrolid
glucocorticoid
might
provid
posit
effect
treatment
cr
upregul
interferon
isg
express
j
allergi
clin
immunol
chronic
rhinosinus
cr
heterogen
mucos
inflamm
involv
paranas
sinus
also
nose
abnorm
host
respons
infecti
microorgan
virus
bacteria
suggest
respons
persist
inflamm
sinonas
mucosa
although
data
preval
viral
infect
patient
cr
conflict
high
frequenc
viral
presenc
demonstr
nasal
epitheli
cell
lavag
fluid
patient
cr
suggest
viral
respiratori
tract
infect
vri
influenc
develop
progress
cours
cr
variou
mean
vitro
studi
demonstr
vri
damag
epitheli
cell
cover
sinonas
caviti
result
dysfunct
epitheli
barrier
increas
bacteri
adhes
interferon
respons
airway
epitheli
cell
critic
defens
viral
infect
requir
suppress
viral
replic
viral
infect
epitheli
cell
line
lower
respiratori
tract
induc
product
antivir
factor
type
ifnb
type
iii
ifnl
interferon
contribut
viru
clearanc
ifnb
ifnl
central
essenti
compon
interferon
respons
airway
epitheli
cell
viral
infect
antivir
immunomodulatori
effect
mediat
sever
interferonstimul
gene
isg
includ
code
viperin
oligoadenyl
synthetas
oa
myxoviru
resist
protein
inhibit
viral
replic
abnorm
innat
immun
respons
vri
report
increas
suscept
viral
infect
patient
chronic
obstruct
pulmonari
diseas
copd
asthma
cystic
fibrosi
trigger
diseas
exacerb
airway
epitheli
cell
asthmat
patient
produc
less
ifnb
ifnl
show
defici
innat
immun
rhinoviru
infect
ifnb
level
also
reduc
epitheli
cell
obtain
children
wheez
atopi
respiratori
syncyti
viru
infect
howev
studi
evalu
whether
appar
defici
antivir
immun
interferon
respons
might
repres
defici
innat
immun
respons
patient
cr
interferon
respons
vri
occur
pattern
recognit
receptor
tolllik
receptor
tlr
implic
respons
viral
infect
doublestrand
rna
recognit
singlestrand
rna
recognit
howev
role
virusrecogn
normal
inflammatori
sinu
mucos
tissu
establish
glucocorticoid
oral
intranas
macrolid
antibiot
treatment
recommend
patient
chronic
rhinosinus
nasal
polyp
crswnp
patient
chronic
rhinosinus
without
nasal
polyp
crssnp
despit
known
benefici
clinic
effect
glucocorticoid
glucocorticoid
treatment
also
known
enhanc
viral
replic
associ
prolong
viral
isol
nasal
wash
natur
occur
rhinoviru
infect
macrolid
exhibit
antimicrobi
activ
addit
immunomodulatori
properti
inhibit
synthesi
secret
inflammatori
cytokin
nevertheless
data
avail
effect
glucocorticoid
macrolid
express
type
interferon
ifnb
type
iii
interferon
isg
inflam
sinonas
mucosa
patient
crswnp
crssnp
present
studi
undertaken
evalu
whether
type
interferon
ifnb
type
iii
interferon
isg
viperin
oa
express
sinonas
mucos
tissu
healthi
control
subject
whether
express
level
alter
patient
crswnp
crssnp
determin
whether
presenc
viru
nasal
secret
patient
cr
relat
express
level
ifnb
isg
investig
whether
express
level
ifnb
ifnl
isg
affect
crsrelat
cytokin
elucid
whether
express
level
ifnb
ifnl
isg
induc
macrolid
corticosteroid
agonist
patient
crssnp
crswnp
enrol
obtain
inform
consent
studi
classif
crssnp
crswnp
perform
accord
diagnost
criteria
european
posit
paper
endoscop
sinu
surgeri
inflammatori
sinu
mucos
tissu
collect
ethmoid
sinus
patient
crssnp
patient
crswnp
normal
sinu
mucos
tissu
also
collect
ethmoid
sinus
patient
blowout
fractur
endoscop
reduct
surgic
remov
sinu
mucos
tissu
randomli
select
surgeri
kept
analysi
total
rna
protein
also
prepar
cultur
normal
inflammatori
sinonas
epitheli
cell
immunohistochem
histolog
analys
part
sampl
fix
paraformaldehyd
pb
embed
oct
compound
addit
crswnp
histolog
classifi
eosinophil
eosinophilshighpow
field
hpf
noneosinophil
eosinophil
hpf
quantifi
eosinophil
compon
hpf
magnif
ethmoid
sinu
mucos
tissu
stain
hematoxylin
eosin
identifi
presenc
respiratori
tract
viru
sinonas
mucos
tissu
particip
mucos
scrape
perform
middl
meatu
scrape
sampl
transfer
ml
steril
pb
immedi
frozen
store
approv
conduct
research
obtain
review
board
ethic
committe
institut
endoscop
physic
find
radiograph
find
symptom
evalu
previous
describ
clinic
characterist
studi
popul
summar
tabl
patient
symptom
sign
viral
upper
respiratori
tract
infect
uri
preced
month
exclud
studi
symptom
viral
uri
evalu
accord
jackson
scale
addit
exclus
criteria
patient
concomit
bronchial
asthma
aspirinexacerb
respiratori
diseas
aerd
allerg
rhiniti
previou
sinu
surgeri
histori
therapi
antibiot
antihistamin
steroid
within
preced
month
nucleic
acid
extract
mucos
scrape
sampl
use
qiaamp
viral
rna
kit
qiagen
hilden
germani
accord
manufactur
instruct
extract
nucleic
acid
mix
rtpcr
premix
realtim
pcr
system
biorad
laboratori
hercul
calif
use
allplex
respiratori
panel
seegen
seoul
korea
detect
respiratori
tract
virus
includ
adenoviru
rhinoviru
coronaviru
mixtur
incub
minut
revers
transcript
follow
denatur
minut
cycl
pcr
fluoresc
detect
temperatur
posit
test
result
defin
welldefin
exponenti
fluoresc
curv
cross
threshold
cycl
ct
valu
individu
target
epitheli
cell
mechan
harvest
normal
inflammatori
human
sinu
mucos
tissu
digest
dispas
dulbecco
modifi
eagl
lonza
walkersvil
md
cell
centrifug
rpm
minut
supernat
discard
cell
resuspend
plate
fill
bronchial
epitheli
growth
medium
lonza
reach
passag
thereaft
cell
harvest
cultur
airliquid
interfac
ali
splinsert
system
polyethylen
terephthal
mm
pore
size
mm
spl
pocheon
citi
kyung
ki
korea
side
splinsert
fill
bronchial
epitheli
growth
medium
dulbecco
modifi
eagl
lonza
submers
first
day
cultur
medium
chang
day
everi
day
thereaft
ali
creat
day
remov
apic
medium
feed
cultur
basal
compart
cultur
medium
chang
everi
day
initi
ali
experi
use
cultur
epitheli
cell
day
creation
ali
confluent
cultur
epitheli
cell
normal
inflammatori
sinu
mucos
tissu
treat
basal
side
h
cytokin
ngml
tnfa
tgfb
r
system
minneapoli
minn
h
cytokin
ngml
r
system
hour
thereaft
cultur
cell
supernat
harvest
evalu
level
antivir
factor
use
western
blot
elisa
confluent
cultur
normal
inflammatori
epitheli
cell
expos
basal
side
macrolid
dexamethason
tlr
agonist
work
concentr
macrolid
gener
liquefi
powder
form
distil
water
dilut
stock
appropri
volum
cultur
medium
clarithromycin
azithromycin
use
concentr
rang
mmoll
dexamethason
ad
cell
concentr
mmoll
hour
agonist
use
optim
concentr
determin
previou
dose
rangefind
experi
polyinosin
polycytidyl
acid
poli
c
agonist
mgml
invivogen
san
diego
calif
agonist
mgml
invivogen
harvest
cell
supernat
use
isol
mrna
protein
analysi
volum
distil
water
use
liquifi
powder
form
includ
vehicl
control
level
ifnb
supernat
cultur
epitheli
cell
quantifi
use
commerci
elisa
kit
human
ifnb
elisa
kit
human
duoset
elisa
kit
duoset
elisa
kit
accord
manufactur
instruct
cell
viabil
assess
use
bromid
mtt
assay
abcam
cambridg
unit
kingdom
briefli
cultur
cell
stimul
variou
concentr
macrolid
antibiot
dexamethason
tlr
agonist
cell
subsequ
rins
pb
react
mtt
ml
mgml
hour
formazan
crystal
form
cell
dissolv
dimethyl
sulfoxid
measur
mean
spectrophotometri
nm
total
rna
extract
frozen
tissu
cultur
epitheli
cell
use
qiazol
lysi
reagent
qiagen
valencia
calif
revers
transcript
conduct
mmlv
invitrogen
carlsbad
calif
realtim
pcr
conduct
use
sybr
premix
ex
taq
takara
bio
shiga
japan
find
stabli
express
refer
gene
across
sampl
test
refer
gene
dehydrogenas
gapdh
eukaryot
translat
elong
factor
alpha
ribosom
protein
use
realtim
pcr
mean
ct
valu
normal
gapdh
rel
mrna
level
target
gene
analyz
method
primer
sequenc
shown
tabl
articl
onlin
repositori
wwwjacionlineorg
immunohistochem
stain
perform
peroxidaselabel
streptavidinbiotin
techniqu
conduct
without
antigen
retriev
frozen
section
mm
incub
dilut
antibodi
abcam
dilut
antibodi
abcam
antiifnb
antibodi
mgml
abcam
antiviperin
antibodi
dilut
abcam
antibodi
mgml
r
system
antioa
antibodi
mgml
r
system
color
develop
western
blot
frozen
sinu
tissu
cultur
cell
lyse
ripa
buffer
contain
proteas
inhibitor
determin
protein
concentr
protein
separ
sdspage
transfer
onto
polyvinyliden
difluorid
membran
biorad
laboratori
bedford
mass
membran
incub
dilut
antioa
antibodi
antibodi
mgml
r
system
antiviperin
antibodi
abcam
antibodi
abcam
band
detect
enhanc
chemiluminesc
statist
analys
calcul
spss
softwar
window
version
spss
chicago
ill
age
differ
sinonas
outcom
test
score
endoscop
score
among
group
data
obtain
use
realtim
pcr
elisa
western
blot
evalu
use
kolmogorovsmirnov
test
assess
normal
homogen
varianc
normal
distribut
data
anova
bonferroni
post
hoc
test
adjust
multipl
comparison
appli
nonparametr
data
kruskalw
test
dunn
post
hoc
test
use
adjust
multipl
comparison
demograph
clinic
characterist
patient
enrol
studi
detail
tabl
signific
differ
among
group
term
age
sex
distribut
averag
sinonas
outcom
test
score
comput
tomograph
grade
endoscop
score
also
summar
tabl
respiratori
virus
detect
mucos
scrape
sampl
control
subject
sampl
patient
crssnp
patient
crswnp
noneosinophil
patient
crswnp
eosinophil
respiratori
viru
detect
rate
significantli
differ
among
group
tabl
determin
whether
interferonmedi
antivir
respons
activ
inflam
sinonas
mucosa
transcript
protein
level
ifnb
oa
viperin
measur
normal
inflammatori
sinu
mucos
tissu
compar
normal
mucos
tissu
ifnb
oa
viperin
mrna
protein
level
reduc
inflammatori
sinu
mucos
tissu
patient
crssnp
crswnp
fig
b
howev
signific
differ
express
level
among
patient
crssnp
patient
noneosinophil
crswnp
patient
eosinophil
crswnp
fig
b
sinonas
epithelium
first
line
defens
respiratori
tract
virus
investig
level
antivir
factor
cultur
epitheli
cell
normal
sinu
mucos
tissu
inflammatori
epitheli
cell
sinu
mucos
tissu
patient
crswnp
patient
crssnp
result
also
show
reduc
level
ifnb
oa
viperin
cultur
inflammatori
epitheli
cell
patient
crswnp
crssnp
compar
level
seen
normal
epitheli
cell
fig
ce
addit
level
factor
differ
among
inflammatori
epitheli
cell
patient
crssnp
patient
noneosinophil
crswnp
patient
eosinophil
crswnp
fig
ce
date
howev
mechan
involv
reduct
antivir
factor
patient
cr
describ
therefor
investig
whether
crsrelat
cytokin
regul
level
antivir
factor
sinonas
mucosa
cultur
normal
inflammatori
epitheli
cell
incub
h
h
cytokin
level
antivir
factor
determin
mean
elisa
western
blot
compar
unstimul
control
cell
ifnb
level
decreas
cultur
normal
epitheli
cell
treat
fig
b
oa
level
downregul
cell
incub
tnfa
tgfb
wherea
level
show
chang
fig
ch
level
downregul
cell
treat
fig
j
addit
viperin
level
reduc
cell
stimul
tnfa
fig
k
l
b
express
level
ifnb
oa
viperin
mrna
transcript
protein
normal
inflammatori
sinu
mucos
tissu
n
obtain
normal
control
subject
ne
patient
crssnp
n
patient
noneosinophil
crswnp
ncrswnp
n
patient
eosinophil
crswnp
ecrswnp
n
evalu
realtim
pcr
fig
western
blot
fig
b
ce
level
antivir
factor
epitheli
cell
supernat
harvest
cultur
epitheli
cell
differenti
normal
sinu
mucos
tissu
n
inflammatori
sinu
mucos
tissu
patient
crssnp
n
patient
noneosinophil
crswnp
n
patient
eosinophil
crswnp
n
respect
investig
realtim
pcr
fig
c
elisa
fig
western
blot
fig
e
data
present
mean
sem
p
j
allergi
clin
immunol
volum
number
fig
express
level
ifnb
b
c
e
f
oa
g
h
j
viperin
k
l
supernat
cell
harvest
normal
cell
inflammatori
epitheli
cell
incub
tnfa
tgfb
concentr
ngml
hour
evalu
realtim
pcr
fig
c
e
g
k
elisa
fig
b
f
western
blot
fig
h
j
l
upper
panel
locat
fig
h
j
l
show
repres
protein
band
evalu
western
blot
data
independ
experi
present
mean
sem
p
cont
normal
epitheli
cell
without
cytokin
treatment
normal
sinu
mucos
tissu
ne
sinu
mucos
tissu
patient
crssnp
sinu
mucos
tissu
patient
noneosinophil
crswnp
ncrswnp
sinu
mucos
tissu
patient
eosinophil
crswnp
ecrswnp
subsequ
assess
whether
antivir
factor
upregul
sinu
mucos
tissu
patient
crswnp
crssnp
macrolid
therapi
frequent
use
treat
cr
cultur
epitheli
cell
normal
sinu
mucos
tissu
control
subject
inflammatori
sinu
mucos
tissu
patient
crswnp
crssnp
treat
variou
concentr
clarithromycin
azithromycin
cell
viabil
assess
use
mtt
assay
macrolid
concentr
use
affect
cell
viabil
data
shown
stimul
macrolid
hour
level
antivir
factor
measur
use
realtim
pcr
elisa
western
blot
fig
mrna
protein
level
ifnb
upregul
normal
epitheli
cell
inflammatori
epitheli
cell
differenti
patient
crssnp
treat
mmoll
clarithromycin
fig
b
howev
ifnb
level
inflammatori
epitheli
cell
patient
noneosinophil
eosinophil
crswnp
increas
mmoll
clarithromycin
treatment
fig
b
level
upregul
normal
epitheli
cell
treat
mmoll
clarithromycin
inflammatori
epitheli
cell
patient
viperin
k
l
supernat
cell
harvest
cultur
normal
epitheli
cell
deriv
normal
sinu
mucos
tissu
inflammatori
epitheli
cell
deriv
patient
crssnp
crswnp
respect
incub
mmoll
clarithromycin
hour
level
evalu
realtim
pcr
fig
c
e
g
k
elisa
fig
b
f
western
blot
fig
h
j
l
data
independ
experi
present
mean
sem
p
c
nonstimul
cell
normal
sinu
mucos
tissu
ne
sinu
mucos
tissu
patient
crssnp
sinu
mucos
tissu
patient
noneosinophil
crswnp
ncrswnp
sinu
mucos
tissu
patient
eosinophil
crswnp
ecrswnp
j
allergi
clin
immunol
volum
number
crssnp
level
increas
mmoll
clarithromycin
treatment
wherea
inflammatori
epitheli
cell
patient
crswnp
show
upregul
mmoll
clarithromycin
treatment
fig
c
thu
clarithromycintr
cell
exhibit
differenti
increas
level
antivir
factor
compar
nontreat
cell
fig
depend
type
cultur
epitheli
cell
normal
inflammatori
type
antivir
factor
clarithromycin
concentr
similar
find
observ
epitheli
cell
treat
azithromycin
fig
cultur
normal
inflammatori
epitheli
cell
treat
variou
dexamethason
concentr
mmoll
cell
viabil
assess
use
mtt
assay
studi
effect
dexamethason
express
antivir
factor
cell
viabil
affect
base
dexamethason
concentr
use
data
viperin
k
l
supernat
cell
harvest
cultur
normal
epitheli
cell
deriv
normal
sinu
mucos
tissu
inflammatori
epitheli
cell
deriv
patient
crssnp
crswnp
respect
incub
mmoll
azithromycin
hour
level
investig
realtim
pcr
fig
c
e
g
k
elisa
fig
b
f
western
blot
fig
h
j
l
data
independ
experi
present
mean
sem
p
c
nonstimul
cell
normal
sinu
mucos
tissu
ne
sinu
mucos
tissu
patient
crssnp
sinu
mucos
tissu
patient
noneosinophil
crswnp
ncrswnp
sinu
mucos
tissu
patient
eosinophil
crswnp
ecrswnp
viperin
k
l
supernat
cell
harvest
cultur
normal
epitheli
cell
deriv
normal
sinu
mucos
tissu
inflammatori
epitheli
cell
deriv
patient
crssnp
crswnp
respect
incub
approxim
mmoll
dexamethason
hour
level
investig
realtim
pcr
fig
c
e
g
k
elisa
fig
b
f
western
blot
fig
h
j
l
data
independ
experi
present
mean
sem
p
c
nonstimul
cell
normal
sinu
mucos
tissu
ne
sinu
mucos
tissu
patient
crssnp
sinu
mucos
tissu
patient
noneosinophil
crswnp
ncrswnp
sinu
mucos
tissu
patient
eosinophil
crswnp
ecrswnp
shown
level
ifnb
normal
epitheli
cell
increas
dexamethason
treatment
approxim
approxim
approxim
mmoll
respect
fig
af
inflammatori
epitheli
cell
deriv
crssnp
level
ifnb
increas
dexamethason
treatment
approxim
approxim
approxim
mmoll
fig
af
inflammatori
epitheli
cell
patient
noneosinophil
eosinophil
crswnp
ifnb
level
increas
dexamethason
treatment
approxim
mmoll
respect
fig
af
increas
oa
level
also
detect
dexamethasonetr
inflammatori
epitheli
cell
deriv
sinu
mucos
tissu
patient
crswnp
patient
fig
distribut
b
c
e
f
g
h
normal
sinu
mucos
tissu
ne
inflammatori
sinu
mucos
tissu
patient
crssnp
b
f
patient
noneosinophil
crswnp
ncrswnp
c
g
patient
eosinophil
crswnp
ecrswnp
h
arrowhead
indic
superfici
epitheli
cell
small
arrow
indic
blood
vessel
larg
arrow
indic
gland
origin
magnif
b
c
level
mrna
transcript
protein
evalu
use
realtim
pcr
fig
b
western
blot
fig
c
ns
statist
signific
data
independ
experi
present
mean
sem
viperin
k
l
supernat
cell
harvest
cultur
normal
epitheli
cell
deriv
normal
sinu
mucos
tissu
inflammatori
epitheli
cell
deriv
patient
crssnp
crswnp
incub
poli
c
express
level
investig
use
realtim
pcr
fig
c
e
g
k
elisa
fig
b
f
western
blot
fig
h
j
l
data
independ
experi
present
mean
sd
p
cont
nonstimul
cell
normal
sinu
mucos
tissu
ne
sinu
mucos
tissu
patient
crssnp
sinu
mucos
tissu
patient
noneosinophil
crswnp
ncrswnp
sinu
mucos
tissu
patient
eosinophil
crswnp
ecrswnp
crssnp
wherea
oa
level
affect
dexamethasonetr
normal
epitheli
cell
fig
g
h
level
alter
normal
inflammatori
epitheli
cell
treat
dexamethason
fig
j
viperin
level
normal
epitheli
cell
increas
approxim
mmoll
dexamethason
treatment
wherea
inflammatori
epitheli
cell
patient
crssnp
crswnp
viperin
level
increas
mmoll
dexamethason
treatment
respect
fig
k
l
express
level
evalu
realtim
pcr
western
blot
signific
differ
found
normal
inflammatori
sinu
mucos
tissu
fig
type
receptor
commonli
distribut
superfici
epitheli
cell
submucos
gland
blood
vessel
normal
inflammatori
sinu
mucos
tissu
fig
addit
ifnb
viperin
oa
mucos
tissu
commonli
local
superfici
epitheli
layer
submucos
gland
see
fig
articl
onlin
repositori
wwwjacionlineorg
cultur
normal
inflammatori
epitheli
cell
incub
tlr
agonist
investig
whether
viral
infect
induc
express
antivir
factor
sinu
mucosa
level
evalu
antivir
factor
increas
normal
inflammatori
epitheli
cell
treat
poli
c
fig
respiratori
tract
virus
detect
sampl
patient
enrol
studi
nevertheless
type
iii
interferon
well
isg
express
normal
ethmoid
sinu
mucos
tissu
cultur
normal
epitheli
cell
level
decreas
inflammatori
ethmoid
sinu
mucos
tissu
well
cultur
inflammatori
epitheli
cell
deriv
patient
crswnp
crssnp
level
ifnb
viperin
oa
downregul
cultur
normal
epitheli
cell
treat
crsrelat
h
h
cytokin
addit
express
level
ifnb
isg
upregul
normal
inflammatori
epitheli
cell
treat
macrolid
dexamethason
agonist
result
suggest
decreas
level
isg
type
type
iii
interferon
inflammatori
sinu
mucos
tissu
might
induc
crsrelat
h
h
cytokin
elicit
suscept
viral
infect
patient
cr
furthermor
macrolid
glucocorticoid
frequent
use
manag
cr
modul
viral
infectioninduc
cr
exacerb
upregul
express
isg
type
type
iii
interferon
well
establish
vri
act
common
trigger
symptom
exacerb
patient
lower
respiratori
diseas
asthma
copd
virus
detect
patient
exacerb
copd
anoth
studi
report
patient
stabl
copd
healthi
subject
posit
result
picornavirus
among
patient
exacerb
cystic
fibrosi
posit
result
respiratori
tract
virus
wherea
nasal
swab
asymptomat
patient
posit
respiratori
tract
virus
rate
posit
viral
detect
patient
acut
asthma
exacerb
significantli
greater
patient
stabl
asthma
collect
result
suggest
viral
load
significantli
greater
exacerb
group
stabl
group
contrast
detect
rate
respiratori
tract
virus
patient
cr
rang
vri
surveil
studi
upper
respiratori
tract
conduct
determin
preval
respiratori
tract
virus
patient
cr
control
subject
without
cr
without
differenti
stabl
exacerb
cr
author
suggest
differ
might
secondari
differ
sampl
locat
techniqu
sampl
size
geographi
furthermor
report
collect
specimen
summer
month
respiratori
tract
virus
far
less
preval
might
result
lower
detect
rate
viru
patient
cr
hand
viral
infect
hypothes
play
role
pathogenesi
progress
recurr
crswnp
sever
studi
report
rel
greater
frequenc
ebv
infect
nasal
polyp
suggest
caus
role
format
nasal
polyp
studi
respiratori
viru
detect
rate
healthi
control
subject
patient
crssnp
patient
crswnp
noneosinophil
patient
crswnp
eosinophil
signific
differ
observ
normal
inflammatori
sinu
mucos
tissu
lower
detect
rate
like
due
sampl
collect
patient
stabl
cr
without
exacerb
symptom
therefor
studi
requir
evalu
whether
viral
infect
respons
acut
exacerb
cr
symptom
nevertheless
express
ifnb
isg
detect
normal
inflammatori
sinu
mucos
tissu
healthi
control
subject
patient
cr
enrol
present
studi
despit
low
viral
detect
rate
defici
interferon
product
bronchial
airway
epithelium
viral
infect
propos
underli
mechan
symptom
exacerb
recent
studi
show
impair
baselin
interferon
express
airway
epithelium
associ
greater
viral
load
ill
sever
vri
vitro
studi
use
cultur
bronchial
epitheli
cell
show
h
inflammatori
condit
decreas
interferon
level
respons
rhinoviru
infect
contrast
lower
respiratori
tract
remain
unclear
whether
vri
influenc
acut
exacerb
cr
symptom
howev
patient
cr
usual
histori
vri
acut
exacerb
cr
exacerb
occur
winter
viral
infect
preval
result
suggest
respiratori
tract
virus
caus
common
cold
contribut
exacerb
cr
symptom
assess
analyz
express
level
isg
type
ifnb
type
iii
ifnl
interferon
sinu
mucos
tissu
found
level
antivir
factor
lower
sinu
mucos
tissu
patient
cr
healthi
sinu
mucos
tissu
data
agre
result
show
defect
ifnb
ifnl
product
bronchial
airway
epithelium
contribut
impair
viral
control
asthmat
patient
patient
copd
collect
data
impli
low
level
antivir
factor
inflammatori
sinu
epithelium
might
result
defici
innat
immun
respons
vri
patient
cr
furthermor
greater
express
antivir
factor
sinonas
epithelium
might
protect
vriinduc
cr
exacerb
interpret
support
recent
clinic
trial
data
show
ifnb
inhal
effect
prevent
virusinduc
asthma
exacerb
hand
patient
chronic
eosinophil
crswnp
associ
aerd
character
presenc
peculiar
mix
ifng
inflammatori
milieu
promin
express
ifng
observ
suggest
mix
pattern
might
respons
alter
regul
cox
pathway
although
associ
viral
infect
aerd
report
publish
studi
influenza
virus
known
use
prostaglandin
e
signal
pathway
benefit
taken
togeth
studi
suggest
nonsteroid
antiinflammatori
drug
pharmacolog
inhibitor
enzym
use
therapeut
drug
viral
infect
found
ifnb
viperin
oa
level
decreas
cultur
normal
sinonas
epitheli
cell
treat
tnfa
tgfb
express
suppressor
cytokin
signal
mrna
reportedli
increas
bronchial
epitheli
cell
children
sever
asthma
accompani
impair
interferon
product
increas
viral
replic
primari
bronchial
epitheli
cell
healthi
subject
expos
rhinoviru
suppress
ifnl
ifnb
mediat
tgfb
studi
show
inhibit
ifnb
express
lung
epitheli
cell
infect
rhinoviru
suggest
connect
h
cytokin
activ
interferon
express
human
bronchial
epitheli
cell
pretreat
also
significantli
inhibit
rhinovirusinduc
ifnb
express
togeth
data
suggest
crsrelat
cytokin
might
reduc
innat
immun
respons
viral
infect
suppress
ifnb
viperin
oa
express
studi
need
clarifi
issu
benefit
macrolid
antibiot
intranas
oral
steroid
wide
recogn
manag
cr
use
primari
treatment
reduc
mucos
inflamm
patient
cr
macrolid
includ
clarithromycin
azithromycin
josamycin
howev
macrolid
known
exhibit
antiinflammatori
immunomodulatori
activ
recent
studi
shown
clarithromycin
azithromycin
possess
antivir
activ
although
mechan
antivir
effect
macrolid
determin
clarithromycin
suggest
mediat
antivir
effect
decreas
intercellular
adhes
molecul
product
azithromycin
upregul
antivir
substrat
interferon
prevent
virusinduc
episod
azithromycin
antivir
activ
bronchial
cell
patient
cystic
fibrosi
also
associ
stimul
antivir
mechan
increas
express
interferon
isg
result
suggest
azithromycin
pretreat
reduc
rhinoviru
replic
possibl
amplifi
interferonmedi
antivir
respons
studi
clarithromycin
azithromycin
upregul
level
antivir
factor
includ
interferon
cultur
normal
inflammatori
epitheli
cell
healthi
control
subject
patient
crswnp
patient
crssnp
respect
consequ
clarithromycin
azithromycin
might
use
interferon
induc
treat
virusassoci
cr
exacerb
contrast
telithromycin
macrolid
reduc
rhinovir
replic
therefor
express
antivir
factor
might
induc
differ
depend
type
macrolid
although
direct
evid
detriment
effect
glucocorticoid
manag
acut
rhinosinus
cr
exacerb
recent
report
shown
treatment
intranas
glucocorticoid
natur
occur
rhinovir
inflect
induc
prolong
shed
viru
nasal
wash
oral
glucocorticoid
therapi
experiment
rhinoviru
infect
healthi
subject
increas
viral
replic
nasal
wash
nevertheless
topic
corticosteroid
use
clinic
manag
cr
exacerb
viral
rhinoviru
associ
preced
viral
uri
corticosteroid
broad
antiinflammatori
effect
use
adjunct
therapi
resolv
reliev
nasal
congest
found
ifnb
level
increas
normal
inflammatori
epitheli
cell
treat
dexamethason
contrast
thoma
et
al
demonstr
glucocorticoid
treatment
increas
viral
replic
pulmonari
bronchial
epitheli
cell
without
signific
reduct
ifna
ifnb
ifnl
level
vitro
vivo
howev
bochkov
et
al
found
glucocorticoid
budesonid
affect
rhinoviru
replic
interferon
product
vitro
suggest
effect
glucocorticoid
viral
infect
might
vari
depend
cell
type
experiment
environ
research
requir
solv
issu
activ
induc
secret
interferon
express
isg
combat
viral
infect
previou
studi
demonstr
mainli
local
superfici
epitheli
cell
turbin
mucosa
stimul
induc
gmcsf
ifnb
secret
nasal
mucosa
therefor
impair
baselin
virusinduc
express
could
involv
defici
interferon
product
patient
cr
howev
level
differ
normal
inflammatori
sinu
mucos
tissu
distribut
epitheli
layer
submucos
gland
vascular
endotheli
cell
data
suggest
role
interferon
induct
impair
inflammatori
sinu
mucos
tissu
howev
stimul
poli
c
led
upregul
ifnb
isg
cultur
normal
inflammatori
epitheli
cell
wherea
cell
show
interferon
respons
data
highlight
inflammatori
epitheli
cell
might
capac
produc
interferon
isg
activ
suggest
interferon
respons
patient
cr
might
mediat
host
defens
inhibit
virusinduc
exacerb
conclus
interferon
isg
express
normal
sinu
mucos
tissu
downregul
inflammatori
sinu
mucos
tissu
result
suggest
abnorm
innat
immun
respons
vri
might
increas
suscept
viral
infect
patient
cr
nevertheless
macrolid
glucocorticoid
provid
posit
effect
treatment
cr
upregul
interferon
isg
level
clinic
implic
interferon
isg
level
decreas
patient
cr
interferon
isg
level
cultur
cell
increas
treatment
macrolid
dexamethason
provid
possibl
role
effect
prevent
virusinduc
cr
exacerb
